142
Views
21
CrossRef citations to date
0
Altmetric
Review

Potential treatment benefits and safety of roflumilast in COPD: a systematic review and meta-analysis

, , , &
Pages 1477-1483 | Published online: 30 Jun 2016

References

  • GOLD COPD [homepage on the Internet]Global Strategy for the Diagnosis Management and Prevention of COPD (updated 2015) GOLD, the Pocket Guide (updated 2015)2015 Available from: http://www.goldcopd.orgAccessed May 28, 2016
  • Soler-CataluñaJJMartínez-GarcíaMARomán SánchezPSalcedoENavarroMOchandoRSevere acute exacerbations and mortality in patients with chronic obstructive pulmonary diseaseThorax20056092593116055622
  • MiravitllesMAnzuetoALegnaniDPatient’s perception of exacerbations of COPD: the PERCEIVE studyRespir Med200710145346016938447
  • CelliBVestboJJenkinsCRGender differences in mortality and clinical expressions of patients with COPD: the TORCH experienceAm J Respir Crit Care Med2010183331732220813884
  • CurtisJLFreemanCMHoggJCThe immune-pathogenesis of chronic obstructive pulmonary disease: insights from recent researchProc Am Thorac Soc2007451252117878463
  • DiamantZBootJDVirchowJCSumming up 100 years of asthmaRespir Med200710137838817258900
  • Boswell-SmithVSpinaDPageCPPhosphodiesterase inhibitorsBr J Pharmacol2006147S252S25716402111
  • VestboJPrescottELangePAssociation of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study GroupAm J Respir Crit Care Med1996153153015358630597
  • RabeKFBatemanEDO’DonnellDWitteSBredenbrokerDBethkeTDRoflumilast – an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trialLancet200536656357116099292
  • CalverleyPMSanchez-TorilFMcIvorATeichmannPBredenbroekerDFabbriLMEffect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary diseaseAm J Respir Crit Care Med200717615416117463412
  • CalverleyPMRabeKFGoehringUMM2-124 and M2-125 Study GroupsRoflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trialsLancet200937468569419716960
  • FabbriLMCalverleyPMIzquierdo-AlonsoJLRoflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long-acting bronchodilators: two randomised clinical trialsLancet200937469570319716961
  • RennardSICalverleyPMGoehringUMBredenbrokerDMartinezFJReduction of exacerbations by the PDE4 inhibitor roflumilast the importance of defining different subsets of patients with COPDRespir Res2011121821272339
  • LeeSDHuiDSMahayiddinAARoflumilast in Asian patients with COPD: a randomized placebo-controlled trialRespirology2011161249125721848706
  • O’DonnellDEBredenbrökerDBroseMWebbKAPhysiological effects of roflumilast at rest and during exercise in COPDEur Respir J2012391104111221965226
  • ZhengJYangJZhouXRoflumilast for the treatment of COPD in an Asian population: a randomized, double-blind, parallel group studyChest20141451445224135893
  • MartinezFJCalverleyPMGoehringUMBroseMFabbriLMRabeKFEffect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trialLancet201538585786625684586
  • HigginsJPThompsonSGQuantifying heterogeneity in a meta-analysisStat Med2002211539155812111919